JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The median citation count of JPAD-Journal of Prevention of Alzheimers Disease is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease134
The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention82
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 202170
Aducanumab: Appropriate Use Recommendations53
Lecanemab: Appropriate Use Recommendations43
Aducanumab: Appropriate Use Recommendations Update31
Current State of Self-Administered Brief Computerized Cognitive Assessments for Detection of Cognitive Disorders in Older Adults: A Systematic Review20
Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial20
Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer’s Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial19
Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging17
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer’s Disease Treated with Anti-Amyloid Beta Therapy15
Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease14
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force13
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease10
Socioeconomic Status and Risks of Cognitive Impairment and Dementia: A systematic Review and Meta-Analysis of 39 Prospective Studies9
The Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT): The Study Protocol for an 18-Month, Multicenter, Randomized, Controlled Trial8
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report8
Association of Subjective Cognitive Decline with Risk of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Prospective Longitudinal Studies7
ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA7
Major Cost Drivers in Assessing the Economic Burden of Alzheimer’s Disease: A Structured, Rapid Review6
Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program6
ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan6
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report6
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients6
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland6
Effects of Mindfulness-Based Tai Chi Chuan on Physical Performance and Cognitive Function among Cognitive Frailty Older Adults: A Six-Month Follow-Up of a Randomized Controlled Trial5
Antihypertensive Agents and Incident Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Observational Studies5
Aging, Senescence, and Dementia5
Living Environment, Built Environment and Cognitive Function among Older Chinese Adults: Results from a Cross-Sectional Study5
Programmed Death of Microglia in Alzheimer’s Disease: Autophagy, Ferroptosis, and Pyroptosis5
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review4
Communicating Personal Risk Profiles of Alzheimer’s Disease to Older Adults: A Pilot Trial4
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force4
POSTERS 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021, Boston, USA4
Sex Moderates the Association between Frailty and Mild Behavioral Impairment4
The Effects of Dual-Task Training on Cognitive and Physical Functions in Older Adults with Cognitive Impairment; A Systematic Review and Meta-Analysis4
Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer’s Disease4
Immunotherapy for Alzheimer’s Disease: Current Scenario and Future Perspectives4
Aducanumab Trials EMERGE But Don’t ENGAGE4
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats4
‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings4
Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabece4
Elevated Blood Homocysteine and Risk of Alzheimer’s Dementia: An Updated Systematic Review and Meta-Analysis Based on Prospective Studies4
Digital Screening for Cognitive Impairment – A Proof of Concept Study4
Environmental Distractions during Unsupervised Remote Digital Cognitive Assessment4
Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention4
Effects of Non-Invasive Brain Stimulation on Alzheimer’s Disease4
Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective - Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)3
Early-Onset Subgroup of Type 2 Diabetes and Risk of Dementia, Alzheimer’s disease and Stroke: A Cohort Study3
Geniposidic Acid Confers Neuroprotective Effects in a Mouse Model of Alzheimer’s Disease through Activation of a PI3K/AKT/GAP43 Regulatory Axis3
Effectiveness of Physical Exercise on Alzheimer’s disease. A Systematic Review3
Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects3
Childhood Secondhand Smoke Exposure and Risk of Dementia, Alzheimer’s Disease and Stroke in Adulthood: A Prospective Cohort Study3
The Association between Peanut and Peanut Butter Consumption and Cognitive Function among Community-Dwelling Older Adults3
Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force3
The ‘Aducanumab Story’: Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis’ or Mark a New Beginning?3
Disease Burden and Attributable Risk Factors of Alzheimer’s Disease and Dementia in China from 1990 to 20193
Recruitment of Older African Americans in Alzheimer’s Disease Clinical Trials Using a Community Education Approach3
What Matters to Patients with Alzheimer’s Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions3
Salivary Alpha-Amylase Activity and Mild Cognitive Impairment among Japanese Older Adults: The Toon Health Study3
The Role of Thyroid Dysfunction in Alzheimer’s Disease: A Systematic Review and Meta-Analysis3
Multimodal Preventive Trial for Alzheimer’s Disease: MIND-ADmini Pilot Trial Study Design and Progress3
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults3
Aducanumab: Appropriate Use Recommendations3
Association of a MIND Diet with Brain Structure and Dementia in a French Population3
Cognitive Digital Biomarkers from Automated Transcription of Spoken Language3
Clusters of Dementia Literacy: Implications from a Survey of Older Adults2
Editorial: What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer’s Disease Can Be Used in Clinical Practice?2
Prediction of Cognitive Decline for Enrichment of Alzheimer’s Disease Clinical Trials2
Study Protocol of a Comprehensive Activity Promotion2
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective2
Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer’s Disease2
Low Amino Acid Score of Breakfast is Associated with the Incidence of Cognitive Impairment in Older Japanese Adults: A Community-Based Longitudinal Study2
Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness2
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force2
Tau Pathologies Mediate the Associations of Vascular Risk Burden with Cognitive Impairments in Non-demented Elders: The CABLE Study2
New Hope for Alzheimer’s Disease2
SYMPOSIA - 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA2
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease2
Environmental Enrichment in Murine Models and Its Translation to Human Factors Improving Conditions in Alzheimer Disease2
POSTERS - 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA2
Clinical Research Investigating Alzheimer’s Disease in China: Current Status and Future Perspectives Toward Prevention2
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature2
Protocol for the Brain Health Support Program Study of the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP): A Prospective 12-Month Intervention St2
SYMPOSIA 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021, Boston, USA2
Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis2
Burden of Illness in People with Alzheimer’s Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality2
The Effect of Multidomain Interventions on Global Cognition, Symptoms of Depression and Apathy – A Pooled Analysis of Two Randomized Controlled Trials2
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer’s Disease: An Overview of Tests for Clinical Practice in the United States and Europe2
Evidence-Based Tools for Dietary Assessments in Nutrition Epidemiology Studies for Dementia Prevention2
Mesenchymal Stem Cells Modulate SIRT1/MiR-134/ GSK3β Signaling Pathway in a Rat Model of Alzheimer's Disease1
Association between 9p21-23 Locus and Frailty in a Community-Dwelling Greek Population: Results from the Hellenic Longitudinal Investigation of Ageing and Diet1
Alzheimer's Disease Prevention Health Coaching1
Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD): Study Design and Protocol1
Prevention of Alzheimer’s Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference1
A Novel Computerized Cognitive Stress Test to Detect Mild Cognitive Impairment1
Editorial: Usefulness of Anchor Based Methods for Determining Clinically Meaningful Change in MCI due to AD1
Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer’s Disease1
Therapeutic Targets for Alzheimer’s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report1
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer’s Disease1
Subjective Cognitive Decline in a Registry Sample: Relation to Psychiatric History, Loneliness, and Personality1
How Will Aducanumab Approval Impact AD Research?1
Implications of Emerging Uses of Genetic Testing for Alzheimer’s Disease1
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer’s Treatment1
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice1
Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer’s Disease Continuum1
Editorial: Accelerating Innovations for Enhanced Brain Health. Can Artificial Intelligence Advance New Pathways for Drug Discovery for Alzheimer’s and other Neurodegenerative Disorders?1
Anxiety and Depressive Symptoms and Cortical Amyloid-β Burden in Cognitively Unimpaired Older Adults1
Modulation of Mitochondrial Function as a Therapeutic Strategy for Neurodegenerative Diseases1
The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis1
Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults1
US Adults’ Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging1
Utility of Environmental Complexity as a Predictor of Alzheimer’s Disease Diagnosis: A Big-Data Machine Learning Approach1
The Dawn of a New Era of Alzheimer’s Research and Drug Development1
Neuroprotective Effects of IVIG against Alzheimer’ s Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice1
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab1
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer’s Disease1
A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer’s D1
Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Challenge from PET Acceptance1
Association of Loneliness with Cognitive Functions1
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer’s Disease Predementia1
Obesity and Brain Health: The Impact of Metabolic Syndrome and Cardiorespiratory Fitness on Cognitive Performances in Middle-Aged Obese Women1
Embryo Selection for a Carrier of an Early-Onset Alzheimer’s Disease-Associated Mutation in the PSEN1 Gene1
Association of Preeclampsia with Incident Dementia and Alzheimer’s Disease among Women in the Framingham Offspring Study1
Combined Evidence for a Long-Term, Clinical Slowing Effect of Multinutrient Intervention in Prodromal Alzheimer’s Disease: Post-Hoc Analysis of 3-Year Data from the LipiDiDiet Trial1
Decreased Gray–White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea1
A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study1
Predicting Progression from Normal to MCI and from MCI to AD Using Clinical Variables in the National Alzheimer’s Coordinating Center Uniform Data Set Version 3: Application of Machine Learning Model1
Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults1
Subjective Cognitive Complaints: Comparing the Relation between Self-Reported Versus Informant-Reported Subjective Cognitive Complaints and Cognitive Performances in Cognitively Unimpaired, Mild Cogni1
Fructose Consumption is Associated with a Higher Risk of Dementia and Alzheimer’s Disease: A Prospective Cohort Study1
The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER): Study Design and Protocol1
Associations between Participant Characteristics and Participant Feedback about an Unsupervised Online Cognitive Assessment in a Research Registry1
Evaluation of the Feasibility, Safety and Efficacy of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in People Affected by Moderate to Severe Alzheimer's Disease: A Double-Blind Mask1
Nutrition-Based Approaches in Clinical Trials Targeting Cognitive Function: Highlights of the CTAD 20201
Oral Health as a Risk Factor for Alzheimer Disease1
Roles of Baseline Intrinsic Capacity and its Subdomains on the Overall Efficacy of Multidomain Intervention in Promoting Healthy Aging among Community-Dwelling Older Adults: Analysis from a Nationwide1
Editorial: Appropriate Use Recommendations for Lecanemab1
A Fay-Herriot Model for Estimating Subjective Cognitive Decline among Military Veterans1
Cognitive Performance and Incident Alzheimer’s Dementia in Men Versus Women1
Unsupervised Performance of the CogState Brief Battery in the Brain Health Registry: Implications for Detecting Cognitive Decline1
China Alzheimer’s Disease and Neurodegenerative Disorder Research (CANDOR) -A Prospective Cohort Study for Alzheimer’s Disease and Vascular Cognitive Impairment1
The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging1
Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites1
A UK-Wide Study Employing Natural Language Processing to Determine What Matters to People about Brain Health to Improve Drug Development: The Electronic Person-Specific Outcome Measure (ePSOM) Program1
A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer’s Disease1
Associations of Cardiovascular and Non-Cardiovascular Comorbidities with Dementia Risk in Patients with Diabetes: Results from a Large UK Cohort Study1
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum1
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations1
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer’s Prevention Registry1
Evaluation of the Fiscal Costs and Consequences of Alzheimer’s Disease in Germany: Microsimulation of Patients’ and Caregivers’ Pathways1
Longitudinal Cognitive Decline in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer’s Disease1
Clinicians’ Perspectives on How Disease Modifying Drugs for Alzheimer’s Disease Impact Specialty Care1
Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010 – 20201
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval1
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets1
Alzheimer’s Disease and Aging Association: Identification and Validation of Related Genes1
The Ups and Downs of Amyloid in Alzheimer’s1
How Modifiable Are Modifiable Dementia Risk Factors? A Framework for Considering the Modifiability of Dementia Risk Factors1
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer’s Disease1
Pushing through the Barriers: Peer Advice to Increase Physical Activity and Reduce Dementia Risk from Participants in a Massive Open Online Alzheimer’s Focused Course1
Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force1
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer’s Disease from Frontotemporal Lobar Degeneration1
Clinical Implementation of Lecanemab: Challenges, Questions and Solutions1
Editorial: Lecanemab: Appropriate Use Recommendations – A Commentary from a European Perspective1
A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease1
Association between Dietary Theobromine and Cognitive Function in a Representative American Population: A Cross-Sectional Study1
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review1
Alzheimer’s Disease Research in Japan: A Short History, Current Status and Future Perspectives toward Prevention1
Medical Journey of Patients with Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia: A Cross-sectional Survey of Patients, Care Partners, and Neurologists1
Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population1
A Large Retrospective Cohort Study on the Risk of Alzheimer’s Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer0
Genetically Determined Alzheimer’s Disease Is Associated with Increased Risk of Varicose Vein: A Mendelian Randomization Study0
Childhood Secondhand Smoke Exposure and Risk of Dementia in Adulthood0
Balancing the Conflicting Goals for Treatment of Alzheimer’s Disease with Monoclonal Antibodies0
Editorial: Blood-Based Biomarkers for Alzheimer’s Disease: Are We There Yet?0
Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid0
Editorial: The Future is Now: Advancing Blood-Based Markers0
Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo0
Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults0
Peripheral Blood BRCA1 Methylation Positively Correlates with Major Alzheimer’s Disease Risk Factors0
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)0
Adjudicating Mild Cognitive Impairment Due to Alzheimer’s Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial0
Multimodal Precision Prevention - A New Direction in Alzheimer’s Disease0
Can Virtual Scientific Conferences Facilitate Two-Way Learning between Dementia Researchers and Participants?0
Modifiable Risk Factors for Accelerated Decline in Processing Speed: Results from Three Dutch Population Cohorts0
Relationships of Hypnotics with Incident Dementia and Alzheimer’s Disease: A Longitudinal Study and Meta-Analysis0
Prediction of Alzheimer’s Disease Based on 3D Genome Selected circRNA0
Evaluation of Clinical Meaningfulness of Fortasyn Connect in Terms of “Time Saved”0
Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment0
Letter to the Editor: First Experiences with Amyloid-Related Imaging Abnormalities – Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management0
Usability of a Web-Based Registry for Preclinical Alzheimer’s Disease: Implications from a Cross-Sectional Online Survey0
A Randomized Prospective Survey Targeting Knowledge, Barriers, Facilitators and Readiness to Participation in Dementia Research0
Editorial: Expanding the atn Framework to Further Personalize Therapies0
Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer’s Prevention Trial: A global Perspective from the API Generation Program0
Commentary: Future of Alzheimer’s Disease Treatment: Combination Therapy and Precision Medicine0
Metformin in the Prevention of Alzheimer’s Disease and Alzheimer’s Disease Related Dementias0
Estimates of Current Capacity for Diagnosing Alzheimer’s Disease in Sweden and the Need to Expand Specialist Numbers0
Letter to the Editor: AMBAR: A Therapeutical Approach for Alzheimer’s Disease Patients Regardless of Amyloid Status0
Investigating the Factor Structure of the Preclinical Alzheimer Cognitive Composite and Cognitive Function Index across Racial/Ethnic, Sex, and Aβ Status Groups in the A4 Study0
Determinants of Medical Direct Costs of Care among Patients of a Memory Center0
Objective and Subjective Measurements of Motor Function: Results from the HELIAD Study0
What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?0
Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment0
Lifestyle and Socioeconomic Transition and Health Consequences of Alzheimer’s Disease and Other Dementias in Global, from 1990 to 20190
Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer’s Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer’s Disease Clinical Studies0
Ten Years after the National Alzheimer’s Plan: Dementia Remains a Hidden Syndrome in France0
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD0
Site Readiness Framework to Improve Health System Preparedness for a Potential New Alzheimer’s Disease Treatment Paradigm0
The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice0
Is “Pre-Preclinical AD” Helpful to the EU/US CTAD Task Force?0
Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (AduhelmTM) to Patients Participating in Clinical Trials0
Quantifying Recruitment Source and Participant Communication Preferences for Alzheimer’s Disease Prevention Research0
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer’s Disease Trials0
Fish and Shellfish Consumption, Cognitive Health and Mortality from Alzheimer’s Disease among US Adults Aged 60 and Older0
Association of Cognitive Reserve Indicator with Cognitive Decline and Structural Brain Differences in Middle and Older Age: Findings from the UK Biobank0
Reply to the Letter to the Editor: Response to Concerns Raised on MRI Surveillance and Clinical Implications of ARIA in Disease Modifying Treatment0
Cytomegalovirus Infection and Alzheimer’s Disease: A Meta-Analysis0
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review0
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer’s Disease Progression0
Understanding Online Registry Facilitators and Barriers Experienced by Black Brain Health Registry Participants: The Community Engaged Digital Alzheimer’s Research (CEDAR) Study0
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort0
Beyond Frailty in Alzheimer’s Disease: Should We Move to the Concept of Intrinsic Capacity?0
Dietary Cholesterol and Dementia Risk0
Cohort Effects in Alzheimer’s Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer’s Disease Cooperative Study0
Plasma Oligomer β-Amyloid and White Matter Microstructural Integrity in Cognitively Normal Older Adults According to Cerebral Amyloid Deposition0
The Journal of Prevention of Alzheimer Disease (JPAD) Is Entering Its Second Decade 2014-20240
Multiomics Blood-Based Biomarkers Predict Alzheimer’s Predementia with High Specificity in a Multicentric Cohort Study0
Association between Longitudinal Cerebrospinal Fluid Alzheimer’s Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer’s Dementia Cohort Study0
When It Comes to Lecanemab (and Donanemab), How Might We Think about ‘Reasonable and Necessary’?0
Preferences about Future Alzheimer’s Disease Treatments Elicited through an Online Survey Using the Threshold Technique0
The Impact of Testosterone on Alzheimer’s Disease Are Mediated by Lipid Metabolism and Obesity: A Mendelian Randomization Study0
How Larger Society Can Give a Helping Hand to Worldwide FINGERS0
Erratum to: Cerebral phospho-tau acts synergistically with soluble Aβ42 leading to Mild Cognitive Impairment in AAV-AD rats0
Medical and Psychiatric Risk Factors for Dementia in Veterans with and without Traumatic Brain Injury (TBI): A Nationwide Cohort Study0
Computerized Cognitive Training in Mild Cognitive Impairment: Findings in African Americans and Caucasians0
Age, Sex, Hypertension and HDL-C Alter Serum BACE1 Activity in Cognitively Normal Subjects: Implications for Alzheimer’s Disease0
Digital Clock Drawing as an Alzheimer’s Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults0
The Clinical Trials Alzheimer’s Disease (Ctad) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!0
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials0
Sex Difference in the Association between Prior Fracture and Subsequent Risk of Incident Dementia: A Longitudinal Cohort Study0
The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer’s Biomarker Results to Research Participants0
Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer’s Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project0
Investigating the Impact of Tea Consumption on Cognitive Function and Exploring Tea-Genetic Interactions in Older Adults Aged 65-105 Years: Findings from the 2002−2018 CLHLS Data0
Association of Multi-Domain Factors with Cognition in the UK Biobank Study0
Chronic Pain in Multiple Sites and Dementia: A Vicious Cycle?0
Who Benefited Most from the Internet-Based Conversational Engagement RCT (I-CONECT)? Application of the Personalized Medicine Approach to a Behavioral Intervention Study0
Opportunities for Cellular Rejuvenation in Alzheimer’s Disease: How Epigenetic Reprogramming and Chaperone-Mediated Autophagy Are Enabling Next Generation Therapeutic Approaches0
Translating the Biology of Aging into New Therapeutics for Alzheimer’s Disease: Senolytics0
Personalized Computational Causal Modeling of the Alzheimer Disease Biomarker Cascade0
0.054136991500854